eCiphr®Cardio

• A highly purified population of cardiomyocytes, differentiated from human induced pluripotent stem (iPS) cells (Cellular Dynamics iCell^® Cardiomyocytes), are used.
• The cells are a mixture of spontaneously electrically-active atrial, nodal, and ventricular-like myocytes. They possess typical human heart cell characteristics forming electrically connected syncytial layers that beat in synchrony, and exhibit expected electrophysiological and biochemical responses upon reference drug exposure.
• Viability is maintained for an extended culture periods (up to 2 weeks) allowing for acute and chronic studies.
• Microelectrode array (MEA) is one of the most sophisticated and efficacious technologies for measuring changes in spontaneously-active cells, such as cardiomyocytes and neurons.
• Cyprotex’s eCiphr^®Cardio is a cell-based assay which uses MEA recording to monitor electrophysiological activity by measuring beat rate, field potential duration, amplitude and conduction velocity.
• Unlike the patch-clamp hERG assay, eCiphr^®Cardio assesses changes in all major ion channels implicated in an action potential.
• This cardiac assay provides a unique in vitro system for preclinical drug discovery, cardiotoxicity assessment, disease modelling and high throughput phenotypic screening of drug candidates.

_{1) Wobus AM and Löser P. (2011) Arch Toxicol 85(2); 79-117
2) Peng S et al., (2010) J Pharmacol Toxicol Methods 61(3); 277-286
3) Finlayson K et al., (2004) Eur J Pharmacol 500(1-3); 129-142
4) Nattel S and Quantz MA, (1988) Cardiovasc Res 22(11); 808-817
5) Walker BD et al., (1999) Br J Pharmacol 128(2); 444-450
6) Zhang S et al., (1999) Cir Res 84; 989-998
7) Cheng HC and Incardona J, (2009) J Pharmacol Toxicol Methods 60(2); 174-184
8) Couderc JP et al., (2008) J Electrocardiol 41(6); 595-602
9) Rona G (1985) J Mol Cell Cardiol 17(4); 291-306
10) Paakkari I (2002) Toxicol Lett 127; 279-284
11) MEA, Axion Biosystems}